Thyroid hormone was recently shown to precondition the myo− cardium against ischemia reperfusion [1, 2] . In fact, long−term thyroxin administration increases tolerance of the isolated rat hearts to ischemia reperfusion injury [3, 4] through mechanisms similar to ischemic preconditioning [2] . However, whether this response is mediated by the accompanied neurohormonal changes or it is a direct effect of thyroid hormone has not been elucidated.
Abstract
Growth and stress seem to share common intracellular pathways and activation of growth signaling can increase resistance to stress. Thyroid hormone induces cardiac hypertrophy and pre− conditions the myocardium against ischemia reperfusion injury. The present study investigated whether this response is medi− ated by renin−angiotensin system (RAS). RAS is shown to be activated in hyperthyroidism and is involved in the development of cardiac hypertrophy. Male Wistar rats were treated with L− thyroxin (25 mg/100 g, sc, od) for fourteen days, while normal rats served as controls. In addition, irbesartan (150 mg/kg po), a potent blocker of angiotensin II type 1 receptor (AT1), was given with L−thyroxin for fourteen days. Isolated hearts were perfused in Langendorff mode; after stabilization, they were subjected to 20 min zero−flow global ischemia and 45 min of reperfusion. Thyroxin induced cardiac hypertrophy, which was diminished with irbesartan administration. Post−ischemic recovery of func− tion was increased in thyroxin−treated hearts as compared to controls while ischemic contracture was accelerated and intensi− fied. Irbesartan did not abolish this response. In conclusion, blockade of angiotensin II type 1 receptor with irbesartan pre− serves thyroxin−induced cardioprotection while diminishing car− diac hypertrophy. It is likely that thyroxin−induced cardioprotec− tion is due to a direct effect of thyroid hormone.
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Thyroid hormone´Ischemia reperfusion´Cardiac hypertrophyŔ enin−angiotensin system Angiotensin II is also likely to serve several other functions. Re− cent studies demonstrate that angiotensin II can precondition the heart, whilst activation of AT1 receptor by angiotensin II, pro− duced locally in the myocardium, contribute to the limitation of infarct size mediated by preconditioning. Furthermore, selective blockade of AT1 receptors abolishes the preconditioning effect in the isolated rabbit heart [11 ± 14] .
Thus, apart from being involved in cardiac hypertrophy, the in− creased activation of renin−angiotensin system (RAS) observed, is also likely to contribute to thyroid hormone−induced cardio− protection. Growth and stress share common intracellular sig− naling, while stimulation of growth signaling increases resist− ance to stress [15] . This issue, although of therapeutic impor− tance, has not been previously addressed. Therefore, the present study investigated the role of RAS in thyroxin−induced cardio− protection using irbesartan, a potent inhibitor of angiotensin II AT1 receptor.
Materials and Methods

Animals
Thirty−six Wistar male rats weighing 300 ± 350 g were used for this study. The rats were handled in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No 85 ± 23, revised in 1996).
Induction of hyperthyroidism
Hyperthyroidism was induced in rats by thyroxin administra− tion. L−thyroxin (Sigma Chemicals, St Louis MO, USA) was diluted in normal saline as previously described and given subcuta− neously once daily (250 mg/kg) for 14 days [16] . Control rats were treated with normal saline subcutaneously once daily for 14 days.
Irbesartan administration
Irbesartan (Sanofi−Synthelabo, Montpellier, France), was admin− istered at the dose of 150 mg/kg/day. The drug was diluted in me− thylcellulose 0.6 % and given orally once daily for 14 days. Control rats were given methylcellulose 0.6 % orally once daily for 14 days.
Experimental groups
Three groups were included in this study: a) Rats treated with normal saline and methylcellulose; NORM, n = 11 b) Rats treated with thyroxin and methylcellulose; THYR, n = 13 c) Rats treated with thyroxin and irbesartan, THYR−IRB, n = 12
Experimental procedure a) Five rats from each group were used for the assessment of car− diac hypertrophy and measurement of glycogen levels. Rats were anesthetized by intraperitoneal injection of ketamine hydrochloric acid (150 mg/kg), and heparin (1,000 IU/kg) was given intravenously before thoracotomy. The hearts were rap− idly excised and placed in ice−cold Krebs−Henseleit buffer. The left ventricles were weighed, rapidly placed in liquid nitrogen and then stored at ± 70 8C, in order to be used for glycogen determination. b) Rats from each group were used for the assessment of base− line cardiac performance and response to ischemia reperfu− sion. After anesthesia and heparin administration, the hearts were rapidly excised and mounted on a Langendorff appara− tus as previously described [16] . In this non−ejecting isolated heart preparation, the hearts were perfused in a retrograde fashion at constant flow adjusted to the left ventricular weight, so coronary flow per gram of cardiac tissue was sim− ilar in all the experimental groups. The hearts were perfused with oxygenated (95 % O 2 , 5 % CO 2 ) Krebs−Henseleit buffer at a temperature of 37 8C and were paced at 320 beats/min. A wa− ter−filled balloon was inserted in the left ventricular cavity and measured the left ventricular pressure under isovolumic conditions. After 20 min of stabilization, the hearts were sub− jected to 20 min of zero−flow global ischemia and 45 min of reperfusion. The pacemaker was turned off during the period of ischemia.
Assessment of cardiac hypertrophy
Cardiac hypertrophy was assessed by the measurement of left ventricular weight (LVW in mg) and the ratio of LVW to body weight in g (LVW/BW in mg/g).
Measurement of myocardial glycogen
Glycogen content was measured by enzymatic analysis [17] . Left ventricular tissue was homogenized in 40 mM potassium acetate (pH 4.8).
Homogenates were centrifuged at 12,000 g for 10 min at 4 8C, and the supernatant was incubated with amyloglycosi− dase (Sigma−Aldrich) for 2 h at 37 8C. Glucose liberated from gly− cogen was measured spectrophotometrically at 563 nm using the Amplex red glucose assay kit (Molecular Probes Europe, Lei− den, The Netherlands). Tissue glycogen content was calculated by subtraction of the measured glucose from the total glucose after glycogen hydrolysis with amyloglycosidase. Glycogen con− tents were expressed in mmol of glucose per gram of left ventric− ular weight.
Assessment of baseline and post−ischemic cardiac function
The baseline cardiac function was assessed by measurement of left ventricular developed pressure (LVDP in mmHg) and the pos− itive and negative first derivative of LVDP (+ dP/dt and ± dP/dt in mmHg/sec) at the end of the stabilization period. During ische− mia, minimal ventricular pressure increases, a phenomenon known as ischemic contracture. The severity of ischemic con− tracture was assessed by the time to peak contracture (T max in min) and the magnitude of contracture (C max in mmHg). Post−is− chemic function was assessed by the recovery of the left ventric− ular developed pressure, which was measured at the end of the reperfusion period and was expressed as percentage of the initial value (LVDP %). Left ventricular end−diastolic pressure was meas− ured at 45 min of reperfusion (LVEDP 45 in mmHg).
Statistics
Values are presented as mean (standard error of the mean, SEM). The unpaired t−test and Mann−Whitney U−test were used for dif− ferences between groups; p−values less than 0.05 after a two− tailed test were considered significant. Original Clinical
Results
Cardiac hypertrophy
Thyroxin administration resulted in the development of cardiac hypertrophy. Irbesartan administration diminished, but did not abolish, thyroxin−induced cardiac hypertrophy ( Table 1) .
Ischemic contracture profile
Ischemic contracture profile for all experimental groups is shown in Fig. 1 
Myocardial glycogen levels
Myocardial glycogen levels were found to be decreased in thyr− oxin−treated as compared to normal rats (10.1 (1.1) for NORM vs. 1.7 (0.4) for THYR, p < 0.05). Administration of irbesartan in thy− roxin−treated hearts had no effect on myocardial glycogen levels (2.6 (1.4) for THYR−IRB, p < 0.05 vs. NORM); Fig. 1 b.
Cardiac function and functional response to ischemia reperfusion Increased contractile performance was found in hyperthyroid hearts and this was not altered with irbesartan administration ( Table 1) .
Post−ischemic functional recovery was higher in thyroxin−treat− ed rats as compared to normal rats (40.16 (5.5) for NORM vs. 57.64 (4.5) for THYR, p < 0.05). Administration of irbesartan did not abolish the increased post−ischemic recovery of function in− duced by thyroxin administration (58.3 (4.9) for THYR−IRB, p < 0.05 vs. NORM); Fig. 2 
a.
Left ventricular end−diastolic pressure at 45 min of reperfusion was no different between the experimental groups ± LVEDP 45 was 65.3 (6.5) for NORM, 61.5 (3.9) for THYR and 58.3 (6.6) for THYR−IRB, p > 0.05.
Discussion
Activation of renin−angiotensin system is now recognized to ex− ert several actions on the cardiovascular system [18] . It is in− volved in the development of cardiac hypertrophy and even in the response of the heart to ischemia [19] . Growth and stress seem to share common pathways [15] . Circulating and tissue RAS is activated in hyperthyroid states, but its physiological role is not fully understood. Recent evidence shows that the renin− angiotensin system, and particularly tissue RAS, is involved in the development of thyroid hormone−related cardiac hypertro− phy; blockade of AT1 angiotensin receptor by losartan resulted in reduction of the thyroxin−induced cardiac hypertrophy [5, 10, 20, 21] . This effect was independent from sympathetic acti− vation; hyperthyroidism−induced cardiac hypertrophy was re− duced by losartan even in hyperthyroid rats subjected to sympa− thetic denervation [10] . Furthermore, ACE inhibitors such as cap− topril with dominant action on the circulating RAS did not pre− vent the development of cardiac hypertrophy [20] . Accordingly, in the present study, administration of irbesartan, an AT1 angio− tensin receptor antagonist, produced similar results; thyroxin− induced cardiac hypertrophy was significantly decreased in irbe− sartan treated animals. 
Original Clinical
Several studies have shown that the renin−angiotensin system is also involved in the response of the myocardium to ischemia [19] . Angiotensin II can precondition the heart, while activation of AT1 receptor by angiotensin produced locally in the heart con− tributes to the limitation of infarct size by preconditioning. Fur− thermore, selective blockade of AT1 angiotensin receptor abol− ishes the preconditioning effect. Thyroid hormone−induced car− dioprotection has been shown to be very similar to that of pre− conditioning; both exacerbate ischemic contracture and increase post−ischemic recovery of function in an isolated model of zero− flow global ischemia and reperfusion [2, 21, 23] . Furthermore, in− creased activity of the RAS has also been shown to occur in hy− perthyroid hearts. It is therefore possible that thyroxin−induced cardioprotection involves the activation of RAS.
In the present study, inhibition of AT1 by irbesartan did not abol− ish the protection induced by thyroxin. In fact, post−ischemic re− covery of function was increased after chronic treatment with thyroxin regardless the administration of irbesartan. Further− more, the acceleration and intensification of ischemic contrac− ture observed in those hearts was not abolished with the admin− istration of irbesartan. Exacerbation of ischemic contracture is a consistent finding that characterizes the hyperthyroid heart [1] . This ischemia−induced diastolic dysfunction could be related to the cardiac hypertrophy. However, reduction of thyroxin−in− duced cardiac hypertrophy by b−adrenergic blockade [24] or, in the present study, by AT1 receptor blockade does not abolish this response.
Studies on ischemic preconditioning show that exacerbation of contracture that occurs in preconditioned hearts during ische− mia is due to less energy availability as a consequence of the myocardial glycogen depletion following the preconditioning protocol [23] . Similarly, in our study, myocardial glycogen was shown to be lower in thyroxin−treated hearts with subsequent exacerbation of ischemic contracture. This response was not found to be altered with irbesartan administration.
It appears that thyroid hormone preconditions the heart inde− pendently from RAS or b−adrenergic system [24] . This might be of important therapeutic relevance [25] . It is now recognized that thyroid analogs might prove to be suitable therapeutic op− tions for treating ischemic heart disease [26] .
In conclusion, blockade of angiotensin II type 1 receptor with ir− besartan preserves thyroxin−induced cardioprotection while di− minishing cardiac hypertrophy. Thyroxin−induced cardioprotec− tion is probably due to the direct effect of thyroid hormone. 
